Biogen (BIIB) Change in Intangibles (2011 - 2025)
Biogen (BIIB) recorded quarterly Change in Intangibles of $16.3 million in Q4 2025, up 207.55% quarter-over-quarter from $5.3 million in Q3 2025, and up 8.67% on a YoY basis from $15.0 million in Q4 2024.
Biogen (BIIB) Change in Intangibles (2011 - 2025) Analysis & Trends
Biogen's Change in Intangibles history runs 14 years deep, the most recent figure standing at $16.3 million for Q4 2025.
- In Q4 2025, Change in Intangibles rose 8.67% year-over-year to $16.3 million; the TTM figure through Mar 2026 stood at $21.6 million (down 83.27% YoY), while the FY2025 annual figure was $31.6 million, down 84.67% from the prior year.
- Change in Intangibles was $16.3 million for Q4 2025 at Biogen, up from $5.3 million in the prior quarter.
- In the past five years, Change in Intangibles ranged from a high of $95.0 million in Q3 2024 to a low of $1.0 million in Q4 2022.
- Historically, Change in Intangibles has averaged $20.1 million across 5 years, with a median of $11.7 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Change in Intangibles surged 1400.0% in 2024, then tumbled 94.42% in 2025.
- A 5-year view of Change in Intangibles shows it stood at $16.9 million in 2021, then sank by 94.08% to $1.0 million in 2022, then soared by 1240.0% to $13.4 million in 2023, then grew by 11.94% to $15.0 million in 2024, then advanced by 8.67% to $16.3 million in 2025.
- The last three Change in Intangibles figures came in at $16.3 million (Q4 2025), $5.3 million (Q3 2025), and $10.0 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Intangibless (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -299.30 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.30 Mn |
| Dec 31, 2025 | 16.30 Mn |
| Sep 30, 2025 | 5.30 Mn |
| Sep 30, 2025 | 5.30 Mn |
| Mar 31, 2025 | 10.00 Mn |
| Mar 31, 2025 | 10.00 Mn |
| Dec 31, 2024 | 15.00 Mn |
| Dec 31, 2024 | 15.00 Mn |
| Sep 30, 2024 | 95.00 Mn |
| Sep 30, 2024 | 95.00 Mn |
| Jun 30, 2024 | 9.10 Mn |
| Jun 30, 2024 | 9.10 Mn |
| Mar 31, 2024 | 75.00 Mn |
| Mar 31, 2024 | 75.00 Mn |
| Sep 30, 2023 | 13.40 Mn |
| Sep 30, 2023 | 13.40 Mn |
| Jun 30, 2023 | 16.00 Mn |
| Jun 30, 2023 | 16.00 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Mar 31, 2023 | 5.00 Mn |